Related Experiment Video
Updated: Aug 20, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Interleukin-18: a therapeutic target in rheumatoid arthritis?
Iain B McInnes1, Foo Y Liew, J Alastair Gracie
1Division of Immunology, Infection and Inflammation, University of Glasgow, UK. i.b.mcinnes@clinmed.gla.ac.uk
Abstract:
Interleukin 18 (IL-18), a member of the IL-1 superfamily of cytokines has been demonstrated to be an important mediator of both innate and adaptive immune responses. Several reports have implicated its role in the pathogenesis of rheumatoid arthritis (RA). Although biologic therapy is firmly established in the treatment of a number of inflammatory diseases including RA, partial and non-responder patients constitute residual unmet clinical need. The aim of this article is to briefly review the biology of, and experimental approaches to IL-18 neutralisation, together with speculation as to the relative merits of IL-18 as an alternative to existing targets.
Related Concept Videos
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
The JAK-STAT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents